SystImmune

Systimmune Inc., located in Redmond, Washington, is a clinical stage immune-oncology biopharmaceutical company focused on the development of multi-specific antibody therapies. The company is a wholly owned subsidiary of Biokin Pharmaceutical Co., Ltd., a pharmaceutical company founded in 1996 in Chengdu, China. Biokin Pharmaceutical Co., Ltd has 2 R&D centers, 2 GMP small molecules manufacturing facilities, 1 GMP biological & ADC manufacturing facility and 1 GMP API manufacturing facility. SystImmune and Biokin have two bispecific antibody programs in phase 1 clinical trials, three first-in-class multi-specific antibody programs will be filing IND in 2020.